rituximab
Showing 1 - 25 of 1,252
Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,
Active, not recruiting
- Prolymphocytic Leukemia
- +2 more
- Ibrutinib
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 7, 2022
Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)
Not yet recruiting
- Relapsed/Refractory B-Cell Lymphoma
- FT522
- +4 more
- (no location specified)
Jul 10, 2023
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann
Active, not recruiting
- Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
- +11 more
- Ibrutinib
- +4 more
-
Washington, District of Columbia
- +6 more
Feb 2, 2023
Splenic Marginal Zone Lymphoma Trial in Worldwide (Rituximab, Zanubrutinib)
Not yet recruiting
- Splenic Marginal Zone Lymphoma
- Rituximab
- Zanubrutinib
-
Aarhus, Denmark
- +4 more
Feb 17, 2023
Nephrotic Syndrome in Children Trial in Chongqing (Rituximab, Mycophenolate Mofetil)
Recruiting
- Nephrotic Syndrome in Children
- Rituximab
- Mycophenolate Mofetil
-
Chongqing, Chongqing, ChinaChildren's Hospital of Chongqing Medical University
May 3, 2023
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute
Recruiting
- B Acute Lymphoblastic Leukemia
- +2 more
- Dasatinib
- +4 more
-
Portland, OregonOHSU Knight Cancer Institute
Dec 16, 2022
Post-transplant Lymphoproliferative Disorder Trial in Saint Louis (Polatuzumab vedotin, Rituximab, CHP)
Not yet recruiting
- Post-transplant Lymphoproliferative Disorder
- Polatuzumab vedotin
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Sep 9, 2023
Myasthenia Gravis, Generalized Trial in Roma (Rituximab, Placebo)
Recruiting
- Myasthenia Gravis, Generalized
- Rituximab
- Placebo
-
Roma, ItalyPoliclinico A. Gemelli IRCCS
May 25, 2023
Lymphoid Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin Trial in Madison (Bendamustine, Rituximab, Lenalidomide)
Completed
- Lymphoid Leukemia
- +2 more
- Bendamustine
- +2 more
-
Madison, WisconsinUniversity of Wisconsin
Jan 30, 2023
DLBCL Trial (Acalabrutinib, Rituximab)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- Acalabrutinib
- Rituximab
- (no location specified)
Jul 11, 2023
CNS Lymphoma Trial in Shanghai (Orelabrutinib, Rituximab, Chemotherapy)
Not yet recruiting
- CNS Lymphoma
- Orelabrutinib
- +2 more
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 22, 2023
Primary Ocular Adnexal MALT Lymphoma Trial (Rituximab, Involved Site Radiation Therapy)
Not yet recruiting
- Primary Ocular Adnexal MALT Lymphoma
- Rituximab
- Involved Site Radiation Therapy
- (no location specified)
Sep 26, 2023
Mantle Cell Lymphoma Refractory Trial (Ibrutinib, Venetoclax, Navitoclax)
Not yet recruiting
- Mantle Cell Lymphoma Refractory
- Ibrutinib
- +3 more
- (no location specified)
May 16, 2023
Nephrotic Syndrome in Children, Rituximab Trial in Hangzhou (Rituximab, Steroid)
Not yet recruiting
- Nephrotic Syndrome in Children
- Rituximab
- Rituximab
- Steroid
-
Hangzhou, Zhejiang, ChinaChildren's Hospital, Zhejiang University School of Medicine
Feb 9, 2023
Lymphoma, Mantle-Cell Trial in Shanghai (Zanubrutinib, Rituximab, Bendamustin)
Not yet recruiting
- Lymphoma, Mantle-Cell
- Zanubrutinib
- +2 more
-
Shanghai, Shanghai, ChinaRuijin Hospital
Nov 14, 2023
Prognostic Model of Rituximab in the Treatment of MN
Not yet recruiting
- Idiopathic Membranous Nephropathy
- Rituximab
- (no location specified)
Dec 28, 2022
Renal Transplant Trial in Seoul (Rituximab, intravenous immune globulin)
Completed
- Renal Transplant
- Rituximab
- intravenous immune globulin
-
Seoul, Korea, Republic of
- +1 more
Oct 25, 2022
Idiopathic Membranous Nephropathy Trial in Beijing (Rituximab, Modified Ponticelli regimen)
Recruiting
- Idiopathic Membranous Nephropathy
- Rituximab
- Modified Ponticelli regimen
-
Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
Mar 23, 2023
Recurrent DLBCL, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory DLBCL Trial in United States (drug, other, biological)
Active, not recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +5 more
- Atezolizumab
- +9 more
-
Duarte, California
- +3 more
Nov 17, 2022
Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult Trial in Boston (Epcoritamab, Rituximab)
Not yet recruiting
- Follicular Lymphoma
- Low Grade Non-Hodgkin's Lymphoma, Adult
- Epcoritamab
- Rituximab
-
Boston, MassachusettsDana-Farber Cancer Institute
Mar 13, 2023
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial
Active, not recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Carboplatin
- +5 more
-
Jacksonville, Florida
- +11 more
Jan 12, 2023
Chronic GVHD Trial in Atlanta (Belumosudil, Rituximab)
Not yet recruiting
- Chronic Graft Versus Host Disease
- Belumosudil
- Rituximab
-
Atlanta, GeorgiaNorthside Hospital
Sep 21, 2023
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Houston (Rituximab, Zanubrutinib)
Recruiting
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Rituximab
- Zanubrutinib
-
Houston, TexasM D Anderson Cancer Center
Jul 9, 2022
Large B-cell Lymphoma Trial in Houston (Prednisone, Rituximab, Cyclophosphamide)
Not yet recruiting
- Large B-cell Lymphoma
- Prednisone
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Sep 19, 2023